Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: An open-label, phase 3 trial

Journal of Viral Hepatitis

Volumn 21, Issue 11, 2014, Pages 762-768

  Omata, Masao ^a   Nishiguchi, Shuhei ^b   Ueno, Yoshiyuki ^c   Mochizuki, Hitoshi ^a   Izumi, Namiki ^d   Ikeda, Fusao ^e   Toyoda, Hidenori ^f   Yokosuka, Osamu ^g   Nirei, Kazushige ^h   Genda, Takuya ⁱ   Umemura, Takeji ^j   Takehara, Tetsuo ^k   Sakamoto, Naoya ^l   Nishigaki, Yoichi ^m   Nakane, Kunio ⁿ   Toda, Nobuo ^o   Ide, Tatsuya ^p   Yanase, Mikio ^q   Hino, Keisuke ^r   Gao, Bing ^s   Garrison, Kimberly L ^s   Dvory Sobol, Hadas ^s   Ishizaki, Akinobu ^s   Omote, Masa ^s   Brainard, Diana ^s   Knox, Steven ^s   Symonds, William T ^s   McHutchison, John G ^s   Yatsuhashi, Hiroshi ^t   Mizokami, Masashi ^q   more..

^a Yamanashi Prefectural Central Hospital   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c YAMAGATA UNIVERSITY   (Japan)

^d MUSASHINO RED CROSS HOSPITAL   (Japan)

^e OKAYAMA UNIVERSITY   (Japan)

^f OGAKI MUNICIPAL HOSPITAL   (Japan)

^g CHIBA UNIVERSITY   (Japan)

^h NIHON UNIVERSITY   (Japan)

ⁱ JUNTENDO UNIVERSITY   (Japan)

^j SHINSHU UNIVERSITY   (Japan)

^k OSAKA UNIVERSITY   (Japan)

^l HOKKAIDO UNIVERSITY   (Japan)

^m Gifu Municipal Hospital   (Japan)

ⁿ Akita City Hosp   (Japan)

^o MITSUI MEMORIAL HOSPITAL   (Japan)

^p KURUME UNIVERSITY   (Japan)

^q NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^r KAWASAKI MEDICAL SCHOOL   (Japan)

^s GILEAD SCIENCES   (United States)

^t NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

more..

Author keywords

direct acting antiviral agents; HCV genotype 2; Hepatitis C virus; nucleotide polymerase inhibitor

Indexed keywords

HEMOGLOBIN; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT; URIDINE PHOSPHATE; VIRUS RNA;

ADULT; AGED; ANAPHYLAXIS; ANEMIA; AREA UNDER THE CURVE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMOGLOBIN DETERMINATION; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NEUTROPENIA; OPEN STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; STEADY STATE; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BLOOD; CLASSIFICATION; CLINICAL TRIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; JAPAN; MIDDLE AGED; PATHOLOGY; PHASE 3 CLINICAL TRIAL; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; JAPAN; MALE; MIDDLE AGED; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE; YOUNG ADULT;

EID: 84907997463     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12312     Document Type: Review

References (14)

1. Chung H, Ueda T, Kudo M,. Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology 2010; 53: 39-43.
2. Tanaka J, Kumgai J, Katayama K, et al,. Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995-2000. Intervirology 2004; 47: 32-40.
3. Mizokami M, Tanka Y, Miyakawa Y,. Spread times of hepatitis C virus estimated by the molecular clock differ among Japan, the United States and Egypt in reflection of their distinct socioeconomic backgrounds. Intervirology 2006; 49: 28-36.
4. Thein HH, Yi Q, Dore GJ, Krahn MD,. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and metaregression. Hepatology 2008; 48: 418-431.
5. Toyoda H, Kumada T, Takaguchi K, Shimada N, Tanaka J,. Changes in hepatitis C virus genotype distribution in Japan. Epidemiol Infect 2014.
6. Kumada H, Okanoue T, Onji M, et al,. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol Res 2010; 40: 8-13.
7. Sovaldi (sofosbuvir) Tablets: US Prescribing Information. Foster City, CA: Gilead Sciences, December 2013. Available at: http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi-pi.pdf.
8. Lawitz E, Mangia S, Wyles D, et al,. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887.
9. Jacobson IM, Gordon SC, Kowdley KV, et al,. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-1877.
10. Zeuzem S, Dusheiko GM, Salupere R, et al,. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993-2001.
11. Kirby B, Gordi T, Symonds WT, Kearney BP, Mathias A,. Population pharmacokinetics of sofosbuvir and its major metabolite (GS-331007) in healthy and HCV-infected adult subjects. AASLD Annual Meeting 2013.
12. Kanda T, Imazeki F, Azemoto R, et al,. Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2. Dig Dis Sci 2011; 56: 3335-3342.
13. Inoue Y, Hiramatsu N, Oze T, et al,. Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses. J Viral Hepat 2010; 17: 336-344.
14. Asahina Y, Tsuchiya K, Tamaki N, et al,. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology 2010; 52: 518-527.